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Goldstein'
Benzene is metabolized, primarily in the liver, toa series ofphenolic and ring-opened products and theirconjugates.
The mechanismofbenzene-inducedaplastic anemiaappearstoinvolvetheconcertedactionofseveral metabolites acting
together onearly stemandprogenitorceUs, aswellasonearly blastcells, suchaspronormoblasts andnormoblaststoinhibit
maturation and amplification. Benzene metabolites also inhibitthe functionofmicroenvironmental stromal cells necessary
tosupport thegrowth ofdifferentiating andmaturingmarrowcells. Thenechanismofbenzene-inducedleukemogenesis
islesswell understood. Benzeneand itsmetabolites donotfunctionwell asmutagens but are highlyclastogenic, produc-
ingchromosome aberrations, sisterchromatid exchange, andmicronuclei. Benzene hasbeenshownto bea multi-organ
carcinogen inanimals. Epidemiological studiesdemonstratethat benzeneisahuman leukemogen. Thereisneed to bet-
ter define the lower end ofthe dose-response curve for benzene as a human leukemogen. The application ofemerging
methods in biologically based riskassessmentemploying phannacokinetic and mechanistic data may helptoclarify the
uncertainties in low-dose risk assessment.
Introduction
The biological impacts ofbenzene have been studied in hu-
mans and inanimal models formostofthis century. This review
concentrates on several aspects ofthe biology ofbenzene. We
discuss its metabolic fate, our current understanding of the
mechanism by which itproduces itseffects, attempts todevelop
pharmacokinetic models for its disposition, and, finally, we
discuss the impactofbenzene onhumans. Ouraimis notonlyto
present a synopsis ofthe literature onbenzenetoxicity, butalso
tochallenge investigators to initiate new studies that will lead to
athorough understandingofbenzene asahazardous agentinour
environment.
Metabolism
Benzene isthe smallestand most stablearomatichydrocarbon.
Inorder to betoxic, benzene mustbe metabolizedto reactive in-
termediates (1-3). Available studies suggestthatbenzenetoxicity
is mediated by multiple metabolites acting on multiple cellular
targets (4). Thisdiscussion briefly reviews benzenemetabolism,
mechanism ofmetabolite formation and the chemical reactivi-
ty ofbenzene metabolites in relation to cellular targets. For re-
cent detailed reviews, the reader is referred to Kalf(5), Snyder
and Chatterjee (6), and Yardley-Jones et al. (7).
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Metabolic Pathways
The major metabolism ofbenzene in vivo takes place in the
liver and consists of the formation of ring-hydroxylated com-
pounds (Fig. 1). Early studiesconducted in rabbits(8-10) show-
ed that benzene is hydroxylated to phenol, catechol, hydro-
quinone, and 1,2,4-benzenetriol, which areexcretedasethereal
sulfatesandglucuronides inthe urine (Fig. 2). WorkbyJaffe (11)
andotherinvestigators (12) showedthatbenzenemetabolismalso
involves ring opening as indicated by the urinary excretion of
trans,trans-muconic acid, aring-opened, sixcarbondienedicar-
boxylic acid. The formation oftrans,trans-muconic acid (mu-
conic acid) was definitively established by Parke and Williams
(9), whodemonstrated theexcretionof[ 4C]muconicacid inthe
urine ofrabbits dosed with ['4C]benzene.
The metabolic pathways ofbenzeneoriginally determined in
rabbits were subsequently established in rats and mice (13-16).
Two metabolic pathways appear to be involved, one leading to
ring-hydroxylatedcompounds and onethat involves ring open-
ing of benzene. The hydroxylated compounds are further
metabolized toglucuronide orsulfateconjugates, which areex-
creted intheurine. Theseconjugates aredetoxificationproducts,
becauseconjugation leads totheirelimination andprevents the
formation of toxic intermediates derived from hydroxylated
benzene metabolites. Conjugation withglutathioneand urinary
excretion ofthe mercapturic acid is an additional pathway that
detoxifiesbenzeneoxide, theinitial reactiveintermediateformed
during metabolism ofbenzene tophenol (discussedbelow). The
urinary metabolite muconic acid is at present the only known
ring-opened metabolite formed from benzene in vivo. This
metabolite is a detoxification product of trans,trans-mucon-
aldehyde, a reactive intermediate formed during microsomal
metabolism ofbenzene via ring opening (17).
The initial step in themetabolismofbenzene results inthe for-SNYDER ETAL.
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FIGURE 1. Intermediary metabolism ofbenzene. [0] indicates oxidation without specifying mechanism; GSH, glutathione. Question marks indicated suspected,
but as yet unproven, pathways. Dotted lines leading to 1,2,4-trihydroxybenzene suggest that it may be formed by either pathway.
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FIGURE 2. Urinary metabolites ofbenzene. The sulfate and glucuronide conjugates ofphenol, catechol, and hydroquinone have been characterized. The location
oftheconjugate on 1,2,4-trihydroxybenzene has yet to be established. Theglutathionederivatives, the DNA basederivative andthering-openedproduct are those
which have been identified in urine.
mation ofphenol. Numerous in vitro studies utilizing cellular
fractions or reconstitutedpurified enzyme systems indicatethat
this step involves metabolism ofbenzene by cytochrome P-450
monooxygenase (18). Benzene is a substrate for isozyme P-450
IIEI (19), and P-450 monooxygenases are also active in the
metabolismofphenol to hydroquinone and catechol (20). The
formation ofphenol is believed to involve the intermediate for-
mation ofbenzene oxide followed by rearrangement to phenol
(21). Alternatively, phenol canalsobeformed frombenzene ox-
ide by acid-catalyzed opening ofthe epoxide ring, followed by
o-BENZOOUINONE
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aromatization via loss ofa proton.
Mechanisms ofphenol formation that do not involve an in-
termediate epoxide but rather direct insertion of oxygen or
aromatic hydroxylation (22) may alsoaccount forthe formation
of appreciable amounts of phenol. Phenol formation from
benzene in areconstituted systemcontaining rabbit liver P-450
isozyme LM2 (P-450IIEI) ormicrosomes wasreported tobein-
hibited by thehydroxyl radical scavengers mannitol anddimethyl
sulfoxide (DMS0), as well as by catalase, horseradish perox-
idase, and superoxide dismutase (23). These findings suggest
that the cytochrome P-450-dependent formation ofphenol can
be mediated by hydroxyl radicals most likely generated from
hydrogenperoxide. The latteristhoughttobeformedbydismuta-
tion of superoxide anion radicals released from cytochrome
P-450. Hydroxyl radical-mediatedphenol formation involves ad-
dition ofahydroxyl radical to the benzene ring, resulting in the
formation of a reactive hydroxy cyclohexadienyl radical (24).
Phenol cansubsequently be formedby adismutation reaction as
suggestedbyCohen and Ofodile(25), who investigatedphenol
formation frombenzene in ahydroxylradical-generating Fenton
system. A roleforhydroxyl radicals inthemetabolismofbenzene
tophenol hasalso beensuggestedbyGiorsky andCoon(26), who
concluded that the hydroxyl radical-mediated formation of
phenol is thedominantpathway at micromolarconcentrations,
whereas athigher(millimolar)concentrations, thedirectoxida-
tion by P-450 is quantitatively ofmuch greater importance.
CytochromeP-450mediatedmetabolismofphenolleadstothe
formationofhydroquinoneandcatecholandthesubsequentfor-
mationof1,2,4-benzenetriol. Analternativepathwayforthefor-
mationofcatecholinvolvesmetabolismofbenzeneoxidebyepox-
idehydrolasetobenzene-trans-dihydrodiol, whichisconverted
tocatecholbytheactionofadehydrogenase. Benzeneoxide can
also react with glutathione under the influence ofaglutathione
transferase toeventuallyyieldaprephenylmercapturicacid(6-N-
acetyl-cysteinyl-S-2,4-cyclohexadienol). Underacidicconditions
this metabolite is aromatized by dehydration to S-phenyl-
mercapturic acid, and both compounds have been observed in
urine (27). Thehydroxylated aromaticbenzenemetabolites are
further metabolized to sulfate orglucuronic acidconjugates.
Themetabolite2-(S-glutathionyl)hydroquinonehasbeeniden-
tified in microsomal metabolism mixtures incubated with
benzene orphenol inthepresenceofaddedglutathione(28,29).
It ispresumably formedby the reaction ofglutathionewith ben-
zoquinone, areactive intermediate derived fromtheoxidationof
hydroquinone. Hydroquinone-S-phenyl mercapturic acid deriv-
ed from the metabolism of2-(S-glutathionyl) hydroquinone has
been identified as a urinary metabolite in rats dosed in-
traperitoneally with benzene, phenol, or hydroquinone (30).
Thus, Figure 2 shows that the urinary metabolites ofbenzene
may include theglucuronicandsulfateconjugates ofthephenolic
metabolites, thepremercapturic andthemercapturicacidsderiv-
ed from benzene oxide, the mercapturic acid derived fromp-
benzoquinone, N-7-phenylguanine, derived from aDNA adduct
ofbenzene, and muconic acid.
Microsomal metabolism ofbenzeneleads totheformation of
tmans,trmns-muconaldehyde (Fig. 3), areactive ring-opened, six-
carbon dienedialdehyde(17). Muconaldehyde was also shown
to be formed inaqueoussolutions ofbenzeneirradiated with X-
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FIGURE 3. Intermediary metabolism of muconaldehyde. ALDH, aldehyde
dehydrogenase; ADH, alcoholdehydrogenase. Thepathway with the ques-
tion mark indicates apossible route ofmetabolism.
rays (31,32)presumably viahydroxyl radical-mediatedopening
ofthe benzene ring. These latter studies and others on the hy-
droxyl radical-mediated formation ofphenol suggest that free
radicals mayparticipate in benzene metabolism.
The metabolismofmuconaldehyde(MUC; Fig. 3)by mouse
livercytosol or a mouse liver soluble fraction results in avarie-
ty ofmetabolites that areformedby oxidation and/or reduction
ofthealdehyde functionalgroup(s) (33-35). Initialoxidation or
reduction leads tothealdehyde acidandaldehydealcoholanalog
of MUC, respectively. Subsequent reduction of the aldehyde
group ofthemixed-aldehyde acid MUCanalog oroxidation of
themixed-aldehyde alcoholanalog ofMUC leadstothe forma-
tion of the mixed-hydroxy acid MUC analog, a metabolite in
which onealdehydic functional groupofMUC isreduced tothe
alcohol and one is oxidized to thecarboxylic acid. Interesting-
ly, the initial reduction tothealdehyde alcohol MUC analog is
reversible(G. Witz,unpublisheddata). Themixedaldehyde car-
boxylic acidanalog ofMUC is furthermetabolized to muconic
acid, a urinary metabolite ofbenzene (9,36,37).
Reactive Metabolites in Benzene Metabolism
The major metabolism of benzene takes place in the liver
where it is mediated by cytochrome P-450 monooxygenase.
Metabolism ofbenzenebycytochrome P-450 results inthe for-
mationofbenzeneoxide, anelectrophilic reactive intermediate.
Evidence thatbenzene isindeed metabolized invivo to benzene
oxide comes from studiesby Muelleretal. (38) who identified
N-7-phenylguanine in the urine of rats exposed to 500 ppm
benzene for 8 hr. This adduct is mostlikely formedby reaction
ofbenzeneoxidewiththeN-7 ofguanine, followedby aromatiza-
tionofthebenzeneringvialossofamoleculeofwaterandsubse-
quentdepurinationoftheadductfromDNA. Althoughbenzene
is also metabolized tophenol andotherhydroxylated metabolites
inthebonenmarrow(39),P-450mediatedmetabolisminthistissue
occurstoarelativelylimitedextent. Thisisduetolowlevelsofthis
enzyme system in the bone maffow compared with liver.
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Indirect evidence indicates that muconaldehyde may be
another reactive metabolite formed inthe liver (17). In addition,
the reactive intermediatesp-benzoquinone and o-benzoquinone
may be formed in this tissue by oxidation of hydroquinone and
catechol, respectively. These reactive quinone metabolites and
muconaldehyde are direct-acting alkylating agents capable of
reacting with cellular nucleophiles, including DNA (40,41).
Numerous in vitro and in vivo studies indicate that these me-
tabolites are genotoxic (42-45). Once formed in the liver, it is
unlikely that they survive long enough to reach the bone marrow.
It is possible, however, that reactive benzene metabolites, similar
to other reactive intermediates, may be bound to carriers that
release them after transport to the target tissue. Reactive in-
termediates may also be conjugated to form less reactive in-
termediates or "storage forms" which, after transport, release
the reactive metabolite through deconjugation. A third possibili-
ty germane perhaps to muconaldehyde may consist of me-
tabolism to a less reactive compound, i.e., a mixed aldehyde
alcohol MUC analog (Fig. 3), which itselfmay behematotoxic
or is subsequently reactivated in the target tissue by metabolism
to the original reactive metabolite, i.e., muconaldehyde.
Thebonemarrow hasbeenshowntoaccumulatehydroquinone
and catechol (46,47), twophenolic metabolites ofbenzene. As
discussed above, bone marrow, unlike the liver, contains low
levels of cytochrome P-450 and high levels of peroxidases.
Phenolic compounds are excellent electron donors for the
peroxidase-mediated metabolism ofhydrogen peroxide. Studies
by Eastmond et al. (48,49) and Sadleretal. (50) have shown that
phenol, catechol, and hydroquinone are excellent substrates for
myeloperoxidase, a peroxidase present in high concentrations in
the bone marrow. During myeloperoxidase metabolism, these
phenolic metabolites undergo one-electron oxidation and co-
valent binding to protein. The reactive species involved in the
binding arepresumably radical intermediates, suchas the semi-
quinone free radical ofhydroquinone, which are formed during
one-electron oxidation.
Para-benzoquinone isareactivec3,,3unsaturateddiketone that
hasbeen implicated in bone marrow toxicity (51,52). Phenol and
catechol have been shown to stimulate the myeloperoxidase
dependent conversion of hydroquinone to p-benzoquinone
(52,53). Basedonthese studies, Smithetal. (54) proposedatwo-
step mechanism ofbenzene toxicity that involves metabolism to
phenolic compounds inthe liver, transport and accumulation of
these compounds in the bone marrow, followed by myelo-
peroxidase-mediated conversion of hydroquinone to p-
benzoquinone in a process stimulated by phenol and possibly
catechol. This mechanismofp-benzoquinone formation does not
exclude a similar involvement by prostaglandin (H) synthetase
and eosinophil peroxidase in benzene toxicity (55).
Mechanisms of Benzene Toxicity
The most frequently observed toxic effect of benzene in
humans and inanimal models usedforthe study ofbenzene tox-
icity hasbeenbonemarrowdepressionleading toaplastic anemia
(14). The correlationbetween the effects ofbenzene exposure in
humans and the effects produced in animal models was dem-
onstrated by Santesson in 1897 (56), Selling in 1916 (57) and
Weiskotten et al. in 1916 and 1920 (58,59). As a result many
studies in animals have been aimed at uncovering the mechanism
ofbenzenetoxicity forthepurposeofapplying theseobservations
toward an understanding ofthe human disease.
During the latter halfofthis century, it has become apparent
thatbenzene also causes chromosomal abnormalities indicative
ofgenetic damage (60-64). Attempts todemonstrate mutagenic
activity of benzene have been largely unsuccessful (42), but
benzene is a human leukemogen (65) and causes solid tumors in
animals (66-68). Unfortunately, thereisnoconvenient model for
studying themechanismsby which benzene produces neoplastic
effects in animals. Although each ofthese effects, i.e., aplastic
anemia, chromosome damage, and carcinogenesis, are in-
dicative ofthe ultimate impact ofbenzene on bonemarrow, the
relationship between these phenomena and the mechanisms by
whichthey are initiated remain tobe fully understood. This sec-
tion describes the effects ofbenzene inmodel systems, discusses
the mechanisms by which these effects occur as we currently
understand them, and points out data gaps, which when filled
may help us to abetter mechanistic appreciation ofthebiological
impact ofbenzene.
Hematopoiesis
The mechanism ofbenzene toxicity has ben examined on the
basis ofits effects on stemand progenitor cells in thebone mar-
row as wellas its effects onthehematopoietic microenvironment.
Hematopoietic stem cells in thebone marrow give rise to the ma-
jorcell typesinthecirculation, i.e., erythrocytes, thrombocytes,
and the several major subdivisions which comprise the leuko-
cytes (69). The self-renewing stem cells which reproduce them-
selves, also yield a cell committed to eventual maturation to a
circulating cell. Growthfactors directcommitted cells to enter
the maturational process, e.g., in the redcell linethecommitted
erythroid cell is sensitive to the initiating action of erythro-
poietin. To assure thatthelevel ofmature cells is constant despite
the regular destruction of aged erythrocytes requires that the
marrow provide amechanism forbothmaturation fromthemor-
phologyoftheprimitive stemcell tothatofthematurecirculating
erythrocyte, plus a mechanism for amplification to sustain the
requisite numberofcirculating erythrocytes, i.e., approximately
5 million cells/4L in humans with a survival time of 120 days.
Thus, acomplex series ofbiosynthetic events results in the pas-
sageofthesecellsthrough several defined morphological stages,
during many of which the cells undergo mitosis to increase
total numbers. A related, but unique process leads tomegakaryo-
cyte production and eventual releaseofplatelets in large numbers
(approximately 250,000/L in humans with a survival time of 10
days). Fewer leukocytes, e.g., between 5 and 12,000 cells/A4L in
most species, are required. However, theprocess iscomplicated
by the need for several different forms including granulocytes,
lymphocytes, monocytes, etc., eachdivided into several function-
al andmorphological subtypesandwithdiffering lifetimes. These
also undergo a series of steps directed by cytokines or other
growth factors involving both maturation and amplification.
Thehematopoieticmicroenvironment iscomposed ofavariety
of cells and structures including endosteal cells, fibroblasts,
reticuloendothelial cells (monocytes and macrophages), fat cells,
and bone and sinusoids ofthe marrow and is responsible for sus-
taining stem and progenitor cells. Proteins such as erythro-
poietin, colony-stimulating factors, the interleukins and related
cytokine mediators are products ofmicroenvironmental cells and
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play key roles indirectingthese events(69). In theabsenceofthe
microenvironment, primitive blood cells cannot mature.
Effects ofBenzene
Many studieshave shown thattreatmentofwholeanimalswith
benzene leads to decrements in the levels ofcirculating blood
cells (14). Mechanistic studieshavebenefitedfromthedevelop-
ment ofa variety ofin vitro techniques. Thus, thebone marrow
ofanimals exposed to benzene using variousexposureprotocols
can be removed and grown in culture to explore the effects of
benzene on specific cell lines at moreor less specific stages of
maturation. Several laboratories havereported ondecreases in
the multipotential hematopoietic stemcell (spleencolony form-
ing unit orCFU-S) in miceafteravariety ofexposureprotocols
(70-73). Similar effects have been observed using the early
granulocyte-macrophageCFU-C assay(72,74). Decreaseshave
also been observed using the erythroid colony-forming unit
(CFU-E) andtheburst-formingcolonyunit (BFU-E) assay, each
of which defines a committed stem cell early in erythrocyte
development (75,76). Exposure ofmice in utero to benzene at
relatively low concentrations resulted in decrements in bone
marrow colony formingunitspostnatally (77,78). Thesestudies
indicate thatbenzeneexertsasignificantimpactonbothprimitive
and early committed stemcells.
In additiontotheeffectsofbenzeneon stemcellsandcommit-
ted stemcells, both morphological andfunctionalevidencehas
linkedbenzene to impairmentoftheprocessesofmaturationand
amplification. Pronormoblasts, normoblasts, andreticulocytes
appear successively at24, 48, and72hrafterreinitiationofred
cell development by erythropoietin (79). Synthesis of hemo-
globin, includingtheincorporationofiron, occursonlybetween
the pronormoblast and reticulocyte stageofcellulardifferentia-
tion (80,81). Onemethodtoobservetheeffectsofchemicals on
various stageoferythropoiesis in vivoinvolvesadministrationof
59Fe intravenously followed by sampling 1 day later ofthe red
cells for incorporationofthe ironintohemoglobin(82,83). This
provides a functional measurement of the reticulocyte pool.
Treatment with chemicals at various times before iron ad-
ministration resultedinadecreaseinironuptake. Thesedatain-
dicate an impairment in red cell development, provided it is
known that the chemical did not interrupt reticulocyte hemo-
globin synthesis. In thecaseofbenzene(82,83)hemoglobin syn-
thesis proceeds normally. Themaximumdecrease inironuptake
following administrationofbenzeneoccurred 48hrbefore iron
administration, atime atwhichthereticulocytes areattheearlier
pronormoblast stageofdevelopment. Normoblastdevelopment
was also inhibited butnoeffectwasobservedinthesestudieson
committed stemcells noronreticulocytes. Takentogether, these
studies suggest effects ofbenzene at both the stemcell and the
progenitor cell stages oferythropoiesis.
Studies by Dexter et al. (84) established a method for the
evaluation ofthehematopoietic microenvironment. The system
allows forthegrowthofanadherentcelllayerofstromalcells in
liquidculture. Stemcellsadded tothispreparationbeginthepro-
cess of maturation and proliferation supported by the stromal
cells. Using this method, Garnett et al. (85) exposed mice to
benzene at various doses, removed the bone marrow, and grew
adherent layers thatsupportedthegrowth, but notthedifferen-
tiation, ofcolony-forming units fromcontrol mice. Inhibitionof
differentiationmay havebeenduetothefailureoftheseprepara-
tions to grow hydrocortisone-induced fat cells essential to
stromal-supporteddifferentiation. Frashetal. (86)exposedmice
toboth radiationandbenzeneand injected normal mouse mar-
row cells. Using the CFU-S technique, they reported failure to
restoremarrowfunction(86). Incubationofbonemarrowcells
withbenzenebeforeinjectionintoirradiatedmicehadnoeffect
onspleencolonyformation. Frashetal. (86)concludedthatthe
hematopoietic microenvironment was damaged as a result of
benzene treatment.
EffectsofBenzene Metabolites
Itappearsthatbenzenetoxicityoccursonlyunderconditions
thatpermittheproductionofbenzenemetabolites. Thus, animals
wereprotected frombenzenetoxicityafterpartialhepatectomy,
whichreducedtotalbenzenemetabolismin vivoandresulted in
adecreaseincovalentbindingofmetabolitesinbonemarrow(2).
his was notthe first suggestion thatbenzene metabolites play a
criticalroleintoxicity. ParkeandWilliams(9), intheirpathfin-
ding report suggested thatthephenolic metabolites ofbenzene
might be responsible for benzene toxicity. A number of in-
vestigators subsequently attempted to identify the toxic me-
tabolitesofbenzene. BothBolscakandNerland(3) andSnyder
and co-workers (87-89) have studied the effects of benzene
metaboliteson59Feuptakeinmiceandfoundthathydroquinone
andcatechol(50-100mg/kg) aremorepotentindecreasing iron
uptakethanphenol. Para-benzoquinone, the metabolicproduct
of hydroquinone, is more potent than hydroquinone.
Muconaldehydeandp-benzoquinonewereeffectiveininhibiting
iron uptake in the range of 1-4 mg/kg.
Several studies have focused on thepossibility that benzene
toxicity is theresultofsynergistic interactions among benzene
metabolites. Eastmondetal. (49) studiedtheeffectofadminis-
tering acombinationofphenol andhydroquinoneandreported
thatthecombinationenhancedtheabilityofeachtoinhibitbone
marrow function. Possibleexplanations forthe interaction be-
tweenhydroquinoneandphenolincludethepreferentialconjuga-
tionofphenolby sulfateandglucuronideleading toagreateref-
fectiveconcentrationoffreehydroquinone, thestimulationofthe
productionofreactivemetabolitesfromhydroquinonebyphenol,
or both. The same interaction was also observed in Snyder's
laboratory (87,88) usingthe 59Fe uptaketechnique.
Guy etal. (89) studiedthe effects ofcombining muconalde-
hydepluseitherhydroquinoneorp-benzoquinone onironuptake
intoerythrocytes. They reportedthatwhenthebinary mixtures
wereadministeredtogether atdoses ofeither which were inef-
fective in reducing iron uptake, the combined effect was to
severely inhibit redcellproduction. Higherdosesalsoindicated
interaction. Multiple regressionanalysis was used to study the
contributions of the components ofthe binary mixtures. The
resultssuggestedthatininhibiting redcellproduction, mucon-
aldehydeandhydroquinone react atthe same site. Muconalde-
hydeandp-benzoquinoneappearto actattwo sites. The nature
ofthese sites are not yetknown, butthese studies suggest that
benzenetoxicity istheresultoftheinteractionbetweenbenzene
metabolites rather than the effect ofa single metabolite acting
independently.
Theeffectsofbenzenemetabolitesonthemicroenvironment
havealsobeenstudied. GaidoandWierda(90-92)evaluatedthe
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effects ofbenzene metabolites on the ability ofadherent cells
from mousebonemarrowtosupportthegrowthofGM-CFU-C
cells. They reported that phenol was not effective below
millimolar concentrations, whereas hydroquinone and benzo-
quinone were the most toxic. Catechol and 1,2,4-benzenetriol
were less potent than hydroquinone and p-benzoquinone.
Previous studies that showedthatDBA/2nmiceweremore sen-
sitive tobenzenetoxicity thanC57/B16mice (93) ledGaidoand
Wierda(90-92)toexaminetherelativeabilityofadherentcells
from B6C3F, and DBA/2J mice to support hematopoiesis.
Although no strain differences wereobserved related tothisac-
tivity, phenol, but not benzene, reduced the ability ofstromal
cells to support the development ofgranulocyte/macrophage
precursor cells.
Stromal macrophages appear to be a significant target in
benzenetoxicity. Forexample, Postetal. (94) foundperoxidase-
mediated metabolism ofphenol to covalently binding species
along withthe inhibitionofRNAsynthesisbyhydroquinoneand
p-benzoquinone. RenzandKalf(95)suggestedthatinthesecells
hydroquinone inhibits theactivationofinterleukin-l andthead-
ministrationofrecombinant interleukin-lIe beforebenzene treat-
mentpreventedbenzenetoxicity inmice. Thesedatasuggestthat
notonly areseveral benzenemetabolites involved inbenzenetox-
icity, but there may also be several targets. Ithas been demon-
strated that stemcells, progenitorcells, and somestromal cells
are sensitive to benzene metabolites.
Genotoxicity
Mutagenicity
Benzene hasnotbeen found toproduce mutagenicity in short-
term tests in vitro (42). The Ames Salmonella test, yeast
mutagenicity test, unscheduled DNA synthesis, mouse lym-
phomatest, 6-thioguanineresistancetestinChinesehamsterV79
cells, the ouabain resistance test in Chinese hamster ovary
(CHO)cells, andhumanlymphoblastHGPRTandTKtestsdid
not indicatethat benzene was a mutagen. Tests aimed at detec-
ting neoplastic cell transformation such as the BALB/c 3T3
mousefibroblasttest, C3H lTl/2 mousecelltest, CHOtest, and
enhancement of viral (SA79) transformation test were also
negative.
There wasa reportthatbenzene yielded apositive Ames test
using strain TAIOO and Aroclor-induced rat livermicrosomes,
taking advantage ofa highly sensitive microflocculation assay
(43,96). Another reportsuggested apositivecell transformation
result inSyrianhamsterembryocells(97). The results suggest
thatexceptforthesetwosystems, eitherthosecellulartargetsthat
wouldhavetobeaffectedtoyieldapositiveresultwerenotsen-
sitive tobenzene, orthenegative results werecausedby the in-
ability ofthose systems toeffectively metabolizebenzenetoreac-
tive intermediatescapableofproducing apositive response. The
hepatic stageofbenzenemetabolisminvivoismediatedprimari-
ly by cytochrome P-450 IIEI, although under some circum-
stancescytochrome-P-450IIBi orothercytochromesP-450may
metabolizebenzene. Furthermetabolicactivationinbonemar-
row cells requires peroxidatic activity. In the absence ofboth
types ofactivating enzymes, mutagenic metabolites will notbe
formed and the results would suggestthatexposure to benzene
would notyield amutagenic effect.
Mutagenicityofbenzenemetabolites, however, hasbeenwell
demonstrated. Thus, Glattetal. (43) studiedthemutagenic ac-
tivity of 13 benzene metabolites using strain TA1535. In the
absence ofS9, trans-1,2-benzenedihydrodiol and benzene diol
epoxides were mutagenic. Dihydrodiol dehydrogenase, which
converts the dihydrodiol to catechol, protected against the
mutageniceffect. Itisthepostulated, butnotdemonstrated, that
thedihydrodiolcanbeconvertedtoaseriesofisomericdiol epox-
ides via a further epoxidation. The anti-diol epoxide was a
mutagen in strains TA97, TA98, TA100, TA102, TA104, and
TA1535. In V79 cells, theanti-diol epoxide also induced sister
chromatidexchange,acquisitionof6-thioguanineresistanceand
ouabainresistance,andmicronuclei. Althoughtheanti-diolepox-
idehasnotbeendemonstratedtobeametabolicproductofbenzene
asyet,thepotentialforitsformationremains,anditmightbeone
ofthemostmutagenicproductsderivedfrombenzene.
Other metabolites effective in the V79 cells were 1,2,4-tri-
hydroxybenzene, hydroquinone, catechol, and thetrans-1,2-di-
hydrodiol whichelevatedresistanceto6-thioguanine. Themost
strikingeffectinthesestudies, however, wasboththepotencyand
greateffectivenessofp-benzoquinone inincreasingthefrequen-
cyof6-thioguanine resistance whilehaving noeffectonouabain
resistance, andproducingnochromosomedamageinV79cells.
Furthermore, p-benzoquinone was relatively ineffective in
Salmonella.
The potential genotoxic activity of trans,trans-muconalde-
hyde, achemically reactive ringopeningproductofbenzene in
microsomalpreparations, wasinvestigated instudiesbyWitzand
co-workers (44,45). Trans,trans-muconaldehyde is generally
highlytoxictocellsin vitro. ItisanactivemutageninV79cells
but is weakly mutagenic in Salmonella (44). In CHO cells
trans,trans-muconaldehyde is apotentclastogen (37,45). Thus,
itappearsthatifbenzenecanundergometabolicactivation, some
ofitsmetabolites, both ringclosedandringopened, canmediate
mutagenic events.
Chromosome Damage
Since the first reports of Pollini and co-workers (98,99),
benzenehasbeenknowntoproducechromosomedamage. They
cultured both bone marrow cells and peripheral lymphocytes
frompatientsdisplaying severebenzenehemopathyandreported
a high rate ofaneuploid cell production. Subsequently, there
weremany reportedobservationsofchromosomeaberrations in
blood from workers exposed tobenzene. Notableamong these
were the reports of Forni and her collaborators (60,61), who
observedchromosomeaberrationsinagroupofworkersexposed
tobenzeneatagreaterfrequencythanworkersexposed totoluene
(60). Follow-upstudiesoftheseworkersrevealedthatbothstable
and unstablebenzene-induced chromosome aberrations occur-
red. The unstable variety eventually disappear, whereas the
stable formpersistand may relate tothe eventualdevelopment
ofleukemia.
Erexson et al. (100) reported that low-dose exposure to
benzene(10-28ppm)over4-6hrproducedsisterchromatidex-
changes (SCE) inperipheral mouseB-lymphocytes. Ticeetal.
(63)demonstratedtheproductionofsisterchromatidexchanges
in mice after short-term exposure to high concentrations of
benzene. Theeffect was exacerbatedwhen the mice were pre-
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treated with phenobarbital, presumably because at these high
doses phenobarbital induces an enzyme that can efficiently
bioactivate benzene. Althoughpartial hepatectomy wasnotpro-
tective, co-administration oftoluene reduced SCEby90%. Witz
et al. (45) reported that administration oftrans,trans-mucon-
aldehyde caused SCE in B6C3F, mice. The data suggested that
benzene metabolites playasignificant roleinproducingSCE.
In cultured human lymphocytes in vitro, it isclearthatbenzene
metabolites induce SCE (101). Phenol, catechol, and hydro-
quinone produced SCE in a dose-dependent manner in the
absence of added metabolic activation, and the effect was
prevented by glutathione. Sister chromatid exchanges were in-
duced with the following order ofpotencies: catechol > 1,4-
benzoquinone > hydroquinone, 1,2,4-benzenetriol > phenol >
benzene.
The report by Hite et al. (62) that benzene produced micro-
nuclei in bone marrow polychromatic erythrocytes in mice led
to the development ofanassay featuring the useofmicronuclei
inperipheral redcellsasarapid screenforchromosomal damage
(102) caused by benzene. Since then micronuclei have been
observed afterbenzene administrationviavariousdoses, routes,
and treatment regimens (5). Harper et al. (103) suggested that
benzene metabolism wasnecessary toyield micronuclei. Pirozzi
etal. (104) demonstratedthatindomethacin, which inhibits the
metabolic activationofphenolic metabolites inbone marrowby
prostaglandin H synthetase (105), also protects against micro-
nucleus formation.
Covalent Binding to Macromolecules
The observations that in the course of its metabolism some
benzene isconverted to reactive metabolites thatcovalently bind
toprotein (106,107) RNAand DNA(108) have ledto a seriesof
studies on the mechanism ofbenzene toxicity.
Irons and Neptun (109)demonstratedthathydroquinone, but
not phenol or catechol, inhibited polymerization of tubulin.
Tubulin possesses nucleophilic sulfhydryl groups that bind
guanosine triphosphate (GI1P), whichin turn stabilizes tubulin
for further polymerization to microtubules necessary for spin-
dle formation during cell division (72). Hydroquinone andp-
benzoquinone interfere with GTP-tubulin bindingby alkylating
SH groups(109,110). Anotherproteinthatisinhibitedby benzene
metabolites, hydroquinone, andp-benzoquinone, butnotphenol
or catechol, is mitochondrial DNA polymerase--y, which also
possesses asulfhydryl groupattheactivesite(111). Thebinding
ofbenzenemetabolites tothesecritical proteins mayplay arole
in benzene toxicity.
The observations of chromosome damage described above
suggestthatthebindingofbenzenemetabolites toDNAmayalso
represent a significant event in benzene toxicity in view ofthe
chromosomedamagediscussedabove. Lutzand Schlatter(108)
exposed rats to either [14C]- or [3H]benzene by inhalation and
found that liver nuclear DNA contained covalently bound
benzene residues, although Lutz (112) notedthatwhencompared
with other carcinogens, relatively little radioactivity derived
frombenzene wasboundto DNA. Rushmoreetal. (113)tookad-
vantage ofthepropertiesofmitochondrial DNA tostudy DNA
bindingby metabolitesofbenzene. Themitochondrioncontains
no mechanism for DNA repair and contains a small circular
DNA. Furthermore, the presenceofacytochrome P-450mono-
oxygenase in mitochondria capable of metabolizing benzene
facilitated production of reactive intermediates (114). Seven
potential DNA adducts on deoxyguanosine and one on deox-
yadenosine were observed, and structures have been proposed
foroneoftheadductsondeoxyguanosine (40) andforthedeox-
yadenosine adduct (115). Neitherthymine norcytosineadducts
were investigated.
Schlosser et al. (105) investigated the oxidation of hydro-
quinone by prostaglandin H synthetase and foundthat whereas
1,4-benzoquinone, theoxidationproductofhydroquinone, was
bound to cysteine or DNA, inhibition of the enzyme by in-
domethacin inhibited both types of binding as well as micro-
nucleusformation(104)andbenzene-inducedmyelotoxicity (116).
The low level ofbinding has made it difficult to detect DNA
adducts in vivo. However, use has been made ofthe 32P-post-
labelingtechniquetomeasurebenzenerelatedadductsbecause
ofitsgreatsensitivity. Baueretal. (117) reported onDNAadduct
formation inrabbitliver. Snyderetal. (87) suggestedthatDNA
adductsare formed inthebonemarrowofbenzene-treated rats.
Usingthe samemethod, Reddy etal. (118) was unabletodetect
DNAadducts frombenzene intheZymbal gland, atargetforthe
carcinogenic activity ofbenzene in the rat, or in bone marrow,
presumably the target for leukemogenic activity. Further
research is needed to determine the role of DNA binding of
benzene metabolites in benzene toxicity and carcinogenesis.
Carcinogenesis
From the mechanistic point of view, benzene-induced car-
cinogenic events havebeendifficultto study becauseofthe lack
ofaconvenientanimal model. Chronicexposureofratsandmice
tobenzenebyinhalation(119) suggeststhatbenzenemightinduce
acuteandchronic myelogenous leukemiaandthymic lymphoma
inthese species. Large scale, chronicexposure studiesby Mal-
toni et al. (66,67) in rats and mice using inhalation or oral ad-
ministrationrevealed theappearanceofZymbal glandtumorsas
well as a variety ofothercancers. These results were confirm-
edand extended in a National Toxicology Program study (68).
However, thesestudieshavenotledtothedevelopmentofmodels
ofuseto study themechanism ofleukemogenesis. A more pro-
mising approach came from Cronkiteetal. (120), who reason-
edthatthedifficulty in producing leukemiaduring chronic ex-
posure is because benzene is an inhibitor ofcell replication, a
process essential to the development of leukemia. Therefore,
theseworkerstreatedmicefor 16weekswith300ppmofbenzene
andthenceasedexposure. Subsequently, noneof88control mice
demonstrated neoplasms, but 8 of 90 benzene-exposed mice
displayedlymphoma/leukemias (120). Thismethodhasyettobe
fullyexploited inthestudyofthemechanismofbenzene-induced
leukemia.
Prevailing theories suggest that initiating events in car-
cinogenesis may becovalentbindingofreactive intermediates to
DNA or oxidative damage of DNA. Subsequent attempts to
eitherrepairorreplicatethe DNA propel the cascadeofevents
termedcarcinogenesis. Furtheranceofthisprocessisthoughtto
require the intervention ofone or more promotional steps that
stimulate proliferation of the genetically altered cells. Alter-
natively, so-called epigenetic events may lead tocarcinogenesis.
Themechanismofbenzenetoxicityhasyettobedefinedwithin
these frameworks.
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Ifweassumethatageneticalterationunderliesthemechanism
of benzene-induced carcinogenesis, we can look toward the
resultsofthegenotoxicity studiescitedaboveas indicatorsofthe
pathway toward neoplasia. Thus, metabolism to reactive in-
termediates would have to be postulated as an important early
step in the mechanism. Itwouldbeexpectedthatbenzeneshould
then stimulate DNA repair, which would be detectable by un-
scheduledDNAsynthesis. However, whenmeasuredinhepato-
cytesandHeLacells, itdidnotappearlikelythatbenzenecaused
DNAdamagesubjecttorepairinmammaliancellsinculture(42).
Subsequenttoageneticchange, itshouldbepossibletomeasure
celltransformation. ThepositiveSyrianhamsterembryotestsug-
gestedthatgiventhepropermetabolicactivatingsystem,benzene
metabolites maybecapableofinducingcelltransformation.
The second step wouldrequirepromotion. Thepossibilitythat
unmetabolizedbenzene mightplayapromotional rolearosefrom
the observations by Da Silva et al. (121) that benzene activates
membrane protein kinase C, which is also activated by tumor
promoters such as phorbol esters. This activity is shared with
toluene, whichproducesneitheraplasticanemia norleukemia.
However, whereas toluene might activate protein kinase C, its
metabolites are neither hematotoxic nor carcinogenic.
Some attempts havebeen made to investigatethemechanism
ofbenzenecarcinogenesis inotherorgans. Reddyetal. (122)and
Low et al. (123) examined the formation of DNA adducts in
Zymbal gland cells in culture and detected DNA binding.
However, adducts were not detected in this organ when the
animals were treated in vivo. Ofperhaps greater significance,
however, were the studies of Busby et al. (124), who treated
newborn mice with benzene, benzene oxide, racemates of
benzene dihydrodiol, andbenzene diol epoxide-1 and benzene
diol epoxide-2. Although benzene and benzene diol epoxide-l
were inactive in this assay, benzene oxide, the racemates of
benzenedihydrodiol, andbenzenediolepoxide-2 inducedlung
tumors in the mice. It is likely that benzene oxide and the
dihydrodiol were metabolized to the diol epoxide-2 to initiate
these tumors. Itwill be importanttoevaluatethelikelihoodthat
thediol epoxide canbe formed inbone marrow in vivotodeter-
mine whether it can be important in leukemogenesis.
One mechanismthatmightexplaintheinitiationofleukemo-
genesisby benzenederives from recentconsiderationsrelating
chromosomeaberrationswith cancer(125). Althoughchromo-
somebreaksand sisterchromatidexchangeshavebeenidentified
as outcomes of benzene exposure, specific studies of the
possibilities ofchromosome translocations have not been per-
formed. Metcalfetal. (126) discussedtherelationship between
translocations and leukemogenesis and recalled thatabout two
dozen nonrandom chromosome translocations have been
reported in both B-cell andT-cell tumors. Oftenthesetransloca-
tions have resulted in thecloseassociationofaproto-oncogene
withagenethatcodes foranimmunoglobulin inaB-lymphocyte
or a T-cell receptor in aT-lymphocyte. The proto-oncogene is
thenderegulatedandcanplay animportantroleleadingtotheex-
pansion aneoplasticclone. Arecentexampleofthisphenomenon
was reportedby deTheetal. (127), whodemonstrated an asso-
ciation ofa specific translocation, designated as t(15;17), with
acutepromyelocytic leukemia, in whichthe neteffect isthe fu-
sion of the retinoic acid receptor, RARa, with a gene called
PML. Theseauthors suggest thatthetranslocation results inthe
formationofanRARmutant, theactivityofwhichistointerfere
withpromyelocyticdifferentiationandthereby facilitatethepro-
cess ofleukemogenesis. Thus, at least three types ofchromo-
some changes caused by benzene metabolites, i.e., gross
chromosomeaberrations, micronuclei, and sisterchromatidex-
change, havebeenreported. Ifbenzenemetabolitescanproduce
translocationsaswell, thismightbeamechanismforleukemo-
genesis that isparallel tothe examplecited above.
Pharmacokinetics of Benzene
Therehavebeenanumberofattempts todeveloppharmaco-
kineticmodelsofthefateofbenzenewiththeintentionofapply-
ingtheresultstoriskassessments forbenzene. Thefirstattempt
to model thefateofbenzene was madeby Sato et al. (128) who
exposed three men to a single exposure of 25 or 100 ppm of
benzene for 2 hr and then observed a triexponential decay of
benzene from their blood. Sato et al. constructed a three-
compartmentmodelmadeupofrichlyperfusedtissues, poorly
perfused tissues, and fat, which acted as a major sink for
benzene. Snyder et al. (18) repetitively exposed mice or rats to
100or300ppmofbenzenefor20daysandsampledthebloodfor
benzene on days 1, 6, and 20. At higher doses mice achieved
greater increases in blood levels ofbenzene than the rats. The
micealsodisplayedagreaterelimination rateconstantthanthe
rats. The rateofbloodbenzenedisappearance frommice atthe
high dose shifted from monoexponential to biexponential be-
tweenthe6thand20thday, whichmayhavebeenduetoenzyme
inductionofbenzenehydroxylase, i.e., cytochromeP-450IIEI.
More recentapproaches haveattemptedto factormetabolism
intophysiologicallybasedpharmacokineticmodelsofthefateof
benzeneandtodevelopamethodforextrapolatingfromanimal
modelstohumans. BelilesandTotman(129)constructedamodel
using Zymbal gland tumors and blood related cancers as end
pointsand, recognizingthepossibilitiesofsynergyandmultiple
mechanisms, assumed that the combined metabolites
represented the "reactive agent." Using largely the data of
Sabourin et al. (13) and applying an allometric technique to
estimate scaling between species, they suggested that their
model, whichpredictsthataworkinglifetimeexposure(40-45
years) to benzene at 10 ppm would result in 6-14 cases of
leukemia/1000, isingoodagreementwithfederalregulatory risk
assessments based onepidemiological data.
Physiologically based pharmacokinetic models aimed at
relatingbenzene metabolismandinterspeciesdifferences, using
bothexperimentaldataandsimulations, havebeendevelopedby
Medinsky etal. (130), Travis et al. (131,132), Bois etal. (133),
and Spear et al. (134). Each described a multicompartment
system and attempted to relate end points to the generation of
metabolites withemphasis onspecificmetabolites assumed tobe
responsibleforgenerating theendpoints under consideration.
Thus, Medinsky etal. (130)consideredtheroleofhydroquinone
andmuconaldehydegenerated in theliverand Bois et al. (133)
added themetabolic activity ofthe bone marrow in the further
metabolism of metabolites generated in liver. While each
representsanimportantadvanceininterpretingthemetabolicfate
of benzene in relation to the development of benzene-related
disease, they all suffer from lack ofsufficient data, as well as
fromvariabilityofthedatabetweenexperimentaldesigns. There
generally is difficulty in fitting empirical data totheoretically
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generated curves, which suggests that the models need to be
improved.
Whereas thedisappearanceofbenzene fromtheblood, follow-
ing administration viaany route, canbemeasured readily, the re-
quirement for metabolism before benzene can produce serious
chroniceffects, makes modelingdifficultbecauseoftheuncer-
tainties pertaining to which metabolites are responsible, the
relative impact of each, and the potential for multiple target
effects.
A large number of metabolites have been described above.
Because oftheir demonstrated, direct effects on bone marrow,
pharmacokinetic models have concentrated on hydroquinone,
alone or incombinationwith phenol, and muconaldehyde, and
forthemostparthaveassumedthatthey areformed inliverand
transportedtothebonemarrow. Thepossibility thatsomeofthe
critical metabolites are ultimately formed in bone marrow serves
tocomplicatethemodeling process. Forexample, althoughthe
metabolites transferred tothebone marrow maybeinnocuous in
themselves, further metabolic activation in bone marrow,
perhapsmediatedbyperoxidases, maygeneratetheultimatetox-
ic metabolites (135). Thus, hydroquinone maybe released from
the liver, free or conjugated, reach the bone marrow by some
mechanism, and in its free form may be oxidized top-benzo-
quinone by a peroxidase. Muconaldehyde might be formed in
bone marrow, and the two working in concert would then pro-
duce a toxic effect. The models wouldhave to reflect these fac-
tors, as well as take into account the activity ofother potential
toxic metabolites, ifthey aretoaccuratelypicturetheprocessand
be used in risk assessment with accuracy.
Human Impact
Benzene isaubiquitous pollutant inboththeworkplace and in
the general environment. Ambient concentrations can be de-
tected worldwide, including pristine areas, although at levels
much lower than in modern urban societies. Major sources of
benzene include petroleum and petroleum products. Levels of
benzene ingasoline rangefromapproximately I to5%. Gasoline
serves as a major sourceofbenzene exposure in awide variety
ofsituations includinggroundwatercontaminationthrough leaky
underground storage tanks; air contamination through the
evaporation of gasoline in workplaces and in homes; and
transdermal exposure whengasolinegets onthe skin. The ma-
jorcauseofhigh-level exposure remains inappropriate use inan
unregulatedworkplace; althoughcontrol measures are leading
toadecreased useofbenzeneasasolventandorganic synthetic
starting block. A major source ofpersonal benzene exposure
comesfromcigarettesmoking(136), andbenzene isalsopresent
insidestream smokeleadingtoexposurethroughpassivesmok-
ing. Althoughthere aremeasurableamountsofbenzene incer-
tain foods, these are nolongerbelievedtobe asignificant source
ofbenzene exposure tothegeneral public, particularly in com-
parison to indoor air pollution from gasoline and benzene-
containing solvents or fromcigarette smokewithinthehome or
the office (137).
Nonhematological Effects
The odor threshold for benzene is in the range of4-5 ppm
(138). The acute nervous system toxicity of benzene appears
similartothegeneralanestheticeffectsoflipophilicsolventsand
is assumed to be a direct effect of benzene unrelated to its
metabolites. Acute symptoms includedrowsiness, lightheaded-
ness, headache, delirium, vertigo, andnarcosis. Levels at which
acutecentral nervous systemeffectsbecomeapparentareatleast
above 100 ppm, an earlier occupational health standard for
benzene, although milder effects could conceivably occur at
lower levels. Based on structure-activity relationships, benzene
might be expected to haveacute central nervous system effects
similar to alkyl benzenes at a slightly lower dose for benzene.
Chronic nervous system effectsofbenzene have notbeenclearly
demonstrated.
Nonhematological tumors have also been demonstrated in
long-termanimal studies(139,140). However, atpresentthere is
no reasonably convincing evidence ofnonhematological solid
tumors occurring in humans exposed to benzene. A meta-
analysis ofbenzene-exposed populations may beofvalue inthis
regard.
Studiesoftheproductive anddevelopmental effectsofbenzene
have shown little aside from hematological effects in the fetus
(77,78). A morethoroughevaluationhasbeencalledforby Davis
and Pope (141).
Immune dysfunction as a result of high-level exposure to
benzene in laboratory animals has been clearly demonstrated
(142). Lymphocytopeniais anearly effectofbenzeneexposure
in animals and in man (143), and there is also evidence sug-
gesting thatthe immune system can be affected by benzene in-
dependentoflymphocytopenia (144). However, thereiscurrently
no evidence to demonstrate an effecton the immune system of
humans exposed to allowable levels ofbenzene.
Hematological Effects
Inhumans, as inanimal models, thebonemarrowisthetarget
ofbenzenetoxicity. Amajorunanswered question aboutbenzene
toxicity concerns its primary localization tothebonemarrow, a
findingthatisalmostuniqueinsolventtoxicology. Aswith many
othersolvents, benzene isprimarily metabolized inthe liver, yet
despite evidence that metabolism is necessary forbone marrow
toxicity, hepatotoxicity isnotobserved. Inessence, therearetwo
different explanations given for bone marrow localization:
specificity in the local metabolism ofbenzene within the bone
marrow orparticularities inthe susceptibility ofthe bone mar-
row, as compared to the liver or other organ, to a benzene
metabolite or metabolites. For example, Subrahmanyam et al.
(135) recently emphasized the potential role offree radicals in
benzene toxicity, pointing out that the relatively high level of
myeloperoxidaseandofotherperoxidasesmayberesponsiblefor
localizationofbenzenetoxicitytothebonemarrow. Incontrast,
Goldstein and Witz (145), noting the relative sensitivity ofthe
bonemarrowtochemotherapeuticalkylating agents, havefocus-
ed on a potential hematologic role for trans,trans-muconalde-
hyde, an ca,3-unsaturated aldehyde alkylating agent which,
althoughhighly reactive, has asufficienthalf-life totheoretically
travel from liver to bone marrow.
Benzene was initially identified as being a human hemato-
logicaltoxininthe 19thcentury. Sincethattimetheliterature is
repletewith casestudiesandseries inwhich fatalaplasticanemia
hasbeenreportedinindividualsexposed tosignificantlevelsof
benzene (146,147). As described above, aplastic anemia is a
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serious, often fatal, disorder in whichthe formed elements ofthe
bone marroware replaced by fatandthere is a significant decre-
ment in the formed elements ofthe blood. Humans may display
adecrease inwhite bloodcells (leukopenia), potentially resulting
in death due to infection; a decrease in platelet count (throm-
bocytopenia), potentially resulting indeath due tohemorrhage;
andadecrease in red blood cell count (anemia). Alesser extent
ofbenzene exposure produces lesser degrees ofdamage to the
bone marrow. The normal human bone marrow has sufficient
reserve capacity to be able to produce approximately six times
more red blood cells under stress than itdoes undernormal con-
ditions. There is also a wide range ofstatistically normal values
in peripheralbloodcounts. Thus, earliest forms ofbone marrow
damageduetoacompound such asbenzene may notbe notable
interms ofadecrease in circulating blood counts. Asdescribed
above, studies in laboratory animals have shown that adecline in
colony forming cells indicative ofthe function and number of
bone marrow precursors can be seen with relatively low levels
ofbenzene exposure. In humans, individuals with benzene ex-
posure may initially have acount lowerthan statistically normal
in any oneofthe formed elements, but with significantexposure,
pancytopenia will be observed (146).
There is awide range between thoseblood countlevels which
are statistically abnormally low and those which produce func-
tional abnormalities. Thus, the rangeofnormal ina laboratory
platelet count is often 150,000-350,000/ttL; yet evidence ofab-
normal hemostasis is usually not observed in humans until the
platelet count is less than50,000/IL. There is, however, some
evidence that in significant benzene toxicity not only is there a
quantitativedecrease in formed bloodcell elements, but there is
also a qualitative alteration. Such qualitative changes might be
expected to interfere with function ofplatelets or white blood
cells. A hallmark ofbenzene effect in red cells is an increase in
average cell size, known as the mean corpuscular volume
(calculated by dividing the hematocrit by the red blood cell
count). An increase inthemeancorpuscular volume also occurs
with folic acid deficiency and vitamin B,2 deficiency, two
disorders which have incommon an interference with DNA syn-
thesis in thebone marrow. An increase in the mean corpuscular
volume is observed inalmost any formofaplastic anemia. As an
increased mean corpuscular volume also occurs relatively ear-
ly in alcoholism, as well as other conditions, it cannot be taken
as a definitive test for benzene exposure at the workplace,
although it can be a useful confirmatory clue (143).
As with any toxicant, there appears to be a variation in the ex-
tent to which individuals differ intheirsensitivity tobenzene, and
some suggestion ofa familial tendency (148). However, there is
noevidence ofan idiosyncratic low-level sensitivitytobenzene-
induced aplastic anemiasimilar to thatobserved with chloram-
phenicol. Interaction with other agents may affectbenzene tox-
icity as described above with respect to ethanol and toluene.
Metabolic interaction between tolueneand benzene would be ex-
pected whenexposure occurs to amixture containing ahigh ratio
oftoluene/benzene because toluene isa competitive inhibitor of
benzene metabolism (1). However, Sato and Nakajima (128)
reported thatthere is no significant interaction between benzene
and toluene with respect to their fate when human experimental
exposure was near the threshold limit value.
Neoplastic Effects
LeNoir and Claude reported the first case of benzene-
associated leukemia in humans in 1897 (149) but the diagnosis
was not well documented. In 1965 Browning (149) recorded 61
cases, andby 1977 Goldstein (146) had assembled 121 cases of
benzene associated leukemia. The studies ofVigliani etal.(150),
Aksoy etal. (151), andInfinte etal. (152), each ofwhich examin-
ed large populations, presented convincing evidence of the
leukemogenic activity ofbenzene.
There isunequivocal evidence thatbenzene is a cause ofacute
myelogenous leukemia (AML), the adult form of acute leu-
kemia. Individual cases inbenzene-exposed individuals began
tobereported in the 1920s, butthe causal relation was not fully
accepted until less thantwo decades ago. This relationship was
firstacceptedby hematologists who have long recognized that
anyone withaplastic anemia fromapparently any cause has an
increased risk ofAML. Forexample, AML as a second tumor
is, unfortunately, common in cancerpatients whose bone mar-
row is affected by radiation and alkylating agents used in
chemotherapy (153). Benzeneexposurealso leads tocytogenetic
abnormalities in bone marrow cells and in circulating lym-
phocytes (60,61).
Epidemiological evidence strongly supportive of the causal
relationship between benzene exposure in theworkplace and
acutemyelogenous leukemia includesstudies ofshoe and other
leatherworkers inItaly and inTurkey (150,154). InTurkey, aglue
used in thefashioning ofleathergoods which had relatively low
levels ofbenzene as asolventwasreplaced inthe 1960s withone
containing muchhigher levels. Soon thereafter, Aksoy and his
colleagues reported a wave of patients with aplastic anemia
followedby identification ofnumerous individuals with AML,
many ofwhomhadpreviously beenidentified as having aplastic
anemia(154,155). Studies oflarge cohorts ofbenzene-exposed
workers inthechemical andpetrochemical industries have tend-
ed to show an increase inhematological neoplasms (156-160).
The mostthoroughly studied cohorthas come from Goodyear
Rubber facilities in Ohio. Repetitive follow-up of a cohort of
workers by the National Institute ofOccupational Safety and
Health (NIOSH) has identified at least 10 cases of acute and
chronic myelogenous leukemia, with only two expected
(152,161,162). To obtain abetter understanding ofthe level and
pattern ofbenzeneexposure associated with this increased risk
of AML, NIOSH has performed one of the most thorough
retrospective exposure assessments ever done on a cohort of
workers (162). Thisexposureanalysis has been used as a basis
for the current risk assessment of benzene by the U.S. En-
vironmental ProtectionAgency(EPA). However, itdoes appear
that NIOSH has significantly underestimated the extent ofex-
posure in theGoodyearplants during World WarII (163,164),
thus leading to some overestimation of the risk of benzene
derived fromthis cohort. However, it should be emphasized that
thecurrent EPA riskassessmentofbenzenehas moreuncertainty
associated with the doseresponse part ofthis equation than it
does with theexposure. Despite the many arguments concern-
ing the extentto which workers who developed AML were ex-
posed to benzene, the differences all lie within an order of
magnitude. Incontrast, thedose-response relationship between
daily environmental benzeneexposure in the range ofparts per
billion and leukemia has a much larger degree ofuncertainty.
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This uncertainty can only be resolved by a better mechanistic
understanding ofbenzene leukemogenesis.
Moreproblematic is thepotential causal relationship between
benzeneandlymphopoietic cancersinhumans. Whileinnocase
is the evidence incontrovertible, there does appear to be more
than sufficientgrounds tolinkbenzeneexposure with multiple
myeloma (165) andperhaps withcertainformsofnon-Hodgkin's
lymphoma and acute lymphoblastic leukemia. In the case of
multiple myeloma the observations include individual case
reports and a statistically significantly increased number of
myeloma cases in the Pliofilm cohort that is under study by
NIOSH (162,166). Inthelattercohort, theassociationhasbeen
suggested to be problematic in view ofthe lack ofrelationship
with the extentofexposure. However, asthere isasmall number
ofcases, it is difficult to expect an obvious dose relationship.
There isa strongelementofbiological plausibilitythatsupports
a causal relationship between benzene exposure and multiple
myeloma, aswell asother lymphatic neoplasms. Lymphocytes
aredefinitely atargetofbenzene, withlymphocytedepletionoc-
curring early in the courseofbenzeneexposure (146,167). The
readily detected cytogenetic abnormalities in lymphocytes
following significant benzeneexposureclearly indicatethatlym-
phocyte DNA is affected as a result ofbenzene exposure, and
there is no question that hematopoietic tissue is subjected to a
carcinogenic metabolite ofbenzene in view oftheclear causal
relationship with acute myelogenous leukemia.
Non-Hodgkin's lymphomas representagrabbagofdifferent
diseases. Acertainportionofthesedisorders reflects severe im-
munedepletionasoccurswith AIDS orsecondarytotreatment
related toorgantransplantation, inwhichthetumorsoccurvery
rapidly, sometimes inlessthan 1 year. However, thereisnoclear
evidencethatbenzene producesthis formofimmunedepletion.
Non-Hodgkin's lymphoma is observed in certain work groups
that have been exposed to solvents or other chemicals, but the
evidencethatbenzene iscausally related remains suggestivebut
uncertain. Similararguments astobiomedical plausibility could
be used to link benzene exposure to acute lymphoblastic
leukemia, the leukemia mostcommonly observed in children.
However, in view of the fortunate absence of well-defined
populations ofchildren thathavebeenexposed tobenzene, itwill
be particularly difficult to develop the epidemiological data
necessary to evaluate the potential causal relation. Individual
cases in relationship to household benzene exposure are being
observed medically and legally buthave notyetbeenreported in
the clinical literature.
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